Proprietary Data Used to Highlight Likelihood of Drug Approval and Competitive Landscape

New York, October 4, 2005 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced an updated Revere Data Report that identifies companies with expected FDA drug approval decision dates (commonly known as PDUFA dates) in the next three months.

Data from Revere Data’s patented classification system and proprietary drug pipeline database is included to provide insights into each drug candidate’s likelihood of approval and the competition it will face.

The FDA Approval Decisions Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The Report is available on Revere Data’s website. “For investors monitoring the drug development pipelines of pharmaceutical and biotech companies, no milestone is more influential than the PDUFA date,” noted Brian Hill , Director of Research for Revere Data.

"Using this calendar and Revere Data’s exclusive content, customers can quickly focus on companies that have potentially high-impact events on the horizon."

Specifically, the FDA Approval Decisions Report provides a three-month calendar of expected PDUFA dates, along with detail on whether each drug candidate:

1. utilizes a mechanism of action already approved by the FDA in other drugs

2. faces two or fewer alternative drugs with the same mechanism of action for the same indication

3. would be the first or second FDA-approved drug for the company
"When drugs meet the above criteria, we have seen evidence that they are more likely to gain approval, and to positively impact the company’s stock price," explained Hill. "Attempting to track and assess these drugs without Revere Data would be hugely time-consuming."

Companies profiled in the latest FDA Approval Decisions Report include Abbott, Bristol Myers, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, and Roche.
"This report showcases our unique strength in applying Revere Data’s classification system to mapping the drug pipelines of virtually all publicly traded healthcare companies," said Glen Wolyner, Chief Executive Officer of Revere Data. "We are extremely pleased that our customers continue to provide positive feedback regarding the many benefits this report has to offer."

Revere Data offers clients the flexibility to access its exclusive content through Revere Research, a userfriendly web based platform or Revere Datafeed, data files that can be integrated into research and trading applications as well as algorithms. With either application, users gain access to Revere Data’s intelligent database of U.S publicly traded companies and ADR's not available through other research providers. Revere Data’s clientele includes sellside agency and proprietary traders, buyside traders, hedge fund managers,
portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.

Become a bobsguide member to access the following

1. Unrestricted access to bobsguide
2. Send a proposal request
3. Insights delivered daily to your inbox
4. Career development